The Chicago Entrepreneur

Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer’s treatment donanemab.

Previous post FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
Next post : Meta’s stock heads for longest losing streak in nearly four years